Press Releases

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function

If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) --... (continue reading...)

Dupixent recommended for EU approval by the CHMP to treat patients with COPD

• Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function
• If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade

Paris and Tarrytown,... (continue reading...)

The net asset value (NAV) of EfTEN United Property Fund unit was 10.70 euros at the end of April, increasing by 0.9% over the month. The jump in NAV was related to the investment of the listed fund EfTEN Real Estate Fund AS, whose shares closed on the Tallinn stock exchange at 4% higher than a month ago. The fund's return on unlisted investments was on average 0,4% in April.

In May, EfTEN United Property Fund invested 255 thousand euros in the EfTEN Residential Fund,... (continue reading...)

PRESS RELEASE – REGULATED INFORMATION

Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007... (continue reading...)